Genetic screening for prostate cancer can help identify inherited risks early, guide treatment decisions, and protect your family’s health. At Fred Hutch Cancer Center, we offer expert genetic ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...

The trial design for ARASTEP is highlighted in the following schema: Two special considerations for ARASTEP are that all patients have maximally treated pelvic disease and that metastasis directed ...

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

Scientists developed a 3D-printed ATLAS platform to show how escort cells help prostate cancer survive in the blood, ...

Researchers are developing genomic screening tools to tailor radiation dose and hormone therapy for prostate cancer patients, ...

A team of researchers has constructed the most detailed single-cell map of the adult human prostate to date, cataloging more ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

The UK National Screening Committee (UK NSC) is poised to deliver its recommendations to the Government on Friday regarding expanded prostate cancer screening for men. Currently, the UK lacks a ...

Excess body weight, as measured by BMI, is associated with improved overall survival (OS) in men with advanced prostate cancer, particularly those with metastatic castration-resistant disease, a ...